Successful treatment with narrowband UVB in a recalcitrant case of IgA pemphigus

Costa, Lilian Lemos; Bedrikow, Roberta Buense; Proença, Carolina Contin; Lellis, Rute Facchini

doi:10.1016/j.abd.2021.09.020

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A low to medium dose of prednisolone may be added to the aforementioned medications for control of widespread acute eruptions. In a minority of cases, patients are recalcitrant to dapsone therapy and do not respond to the alternative medications as in our case, such recalcitrant cases have been treated successfully with phototherapy, apremilast, and alitretinoin 14–16 . Also, several case reports highlighted the successful treatment of refractory IgA pemphigus with adalimumab injection alone or in combination with other systemic medication, detailed data provided in Table 1 6,17 .…”

Section: Discussionmentioning

confidence: 62%

“…In a minority of cases, patients are recalcitrant to dapsone therapy and do not respond to the alternative medications as in our case, such recalcitrant cases have been treated successfully with phototherapy, apremilast, and alitretinoin. 14 , 15 , 16 Also, several case reports highlighted the successful treatment of refractory IgA pemphigus with adalimumab injection alone or in combination with other systemic medication, detailed data provided in Table 1 . 6 , 17 The previous studies didn't define the exact time of tapering or discontinuing adalimumab.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case of IgA pemphigus, with a poor response to dapsone, successfully treated with adalimumab

Al‐Zahawi,

Kamyab,

Balighi

2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageIgA pemphigus is usually treated by Dapsone. Recalcitrant cases may be treated by Colchicine, Sulfapyridine, or Acitretin. Some patients with recurrent severe disease may not respond to the aforementioned medications. Our study highlights the role of TNFa inhibitor as an alternative modality in the treatment of recalcitrant IgA pemphigus.AbstractIgA pemphigus is a rare autoimmune blistering disease characterized by a pruritic, annular, vesiculopustular eruption. In IgA pemphigus, there are IgA autoantibodies targeting the keratinocyte cell surface adhesion molecules, causing cell‐to‐cell dehiscence and a flaccid vesiculopustular eruption, mainly in the axilla and groin. Dapsone, despite being the drug of choice for treating IgA pemphigus, is not effective in clearing lesions in a minority of patients and such rare cases of recalcitrant IgA pemphigus need alternative modalities of treatment. Here, we report the successful treatment of a 50‐year‐old male patient with an adalimumab injection who had a poor response to dapsone.

show abstract

Section: Discussionmentioning

confidence: 62%